The European molecular oncology diagnostics industry is experiencing significant growth, driven by several key factors. Rising incidence rates of cancer across Europe, coupled with advancements in molecular diagnostic technologies, are fueling demand for precise and accurate diagnostic tools. Furthermore, the implementation of personalized medicine